|
Psoriasis
|
C0168T38
|
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients with Moderate to Severe Plaque Psoriasis
|
III
|
|
Psoriasis
|
0881A6-101764
|
A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis
|
IIIb/IV
|
|
Psoriasis
|
P04320
|
Study to determine the non inferiory of GROUP I("high need") compared to GROUP II (low need") concerning the efficacy of infliximab with respect to safety and tolerability in patients suffering from chronic plaque psoriasis (psoriasis vulgaris)
|
IIIb
|
|
Psoriasis
|
CDP870/ RPCE05C0901
|
Multicenter, dose response, randomized, double-blind, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certozumab pegol) at 2 different 12 weeks dose regimens (400mg initial dose at week 0 with 200 mg every 2 weeks thereafter and 400 mg every 2 weeks), followed by a minimum of 12 weeks of follow-up without treatment (or until relapse) in subjects suffering from moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy and/or phototherapy and/or photochemotherapy.
|
II
|
|
Psoriasis
|
VB-201-006-A
|
A randomized, double-blind, 12-week, dose ranging, placebo-controlled study to evaluate (1) the efficacy and safety of oral VB-201 on Carotid Artery and ascending Aorta PET 18FDG Uptake in psoriasis patients with abnormal baseline pet18fdg scans
|
II
|
|
Psoriasis
|
C0743T09
|
A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluation the efficacy and safety of CNTO 1275 in the treatmen of subject with moderate Plaque-type psoriasis
|
III
|
|
Psoriasis
|
n.a.
|
A 12-week, double-blind, randomised, placebo-controlled, modified close-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584 XX tablets of doses of 100,300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders;
|
IIa/b
|
|
Psoriasis
|
C8044/ RPCE05L1402
|
Follow-up study C87040: Multicenter, single blind study to describe the efficacy and safety of re-treatment with CDP870 (certolizumab pegol) subcunateous at 2 different dose regimens (400 mg intial dose at week 0 with 200 mg every 2 weeks thereafter and 400 mg every 2 weeks) or placebo for 12 weeks, in subjects suffering from moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy and/or phototherapy and/or Photochemotherapym having responded to treatment in study C87040 and having subsequently relapsed
|
II
|
|
Psoriasis
|
ISA05-25
|
A Phase III, Randomized, Multicenter, Double-Blind, Placebo and Ciclosporine Controlled Study of ISA247 in Plaque Psoriasis Patients (ISA 05/25)
|
III
|
|
Psoriasis
|
C0743T12
|
Eine multizentrische, randomisierte Studie zum Vergleich von CNTO 1275 und Etanercept in der Behandlung von mittelschwerer bis schwerer Psoriasis vulgaris, Phase III;
|
III
|
|
Psoriasis
|
0881A6-3326
|
A 3 month, randomised, open label, parallel group descriptive study to explore and compare perceptions and satisfaction for two different delivery machanisms for etanercept (Etanercept auto injector and the etanerecept prefilled syringe) in patients with rheumatoid arthritis;
|
III
|
|
Psoriasis
|
M10-060
|
A Multi-center, Randomized, Vehicle-controlled Study to Assess the Efficacy and Safety of Adamilumab in Combination with Topical Treamtent (Calcipotriol/Bethamethasone) in Subjects with Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE), Site 1719
|
IIIb
|
|
Psoriasis
|
AC-058A200
|
Multicenter, randomized, double-blind, placebo-controlled, Phase Iia study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subjects with moderate to severe chronic plaque psoriasis;
|
IIa
|
|
Psoriasis
|
M41008-1102
|
A multi-center, randomized, double-blinded, three-arm, 16 week, adaptive phase III clinical study to investigate the effiacy and safety of LAS41008 vs LASW1835 and vs placebo in patients with moderate to severe chronic plaque psoriasis
|
III
|
|
Psoriasis
|
066-007/08
|
Eine multizentrische, randomisierte, doppel-blinde, placebo-kontrollierte intraindividuell-vergleichende Phase Iia-Studie zur Wirksamkeit und Sicherheit der Anwendung von 2 % AVT-02UE-Salbe an jedem zweiten Tag in der Behandlung von leichter bis mittelschwerer Psoriasis vulgaris;
|
IIa
|
|
Psoriasis
|
Gepard Long Life
|
Identifizierung von Psoriasis-Arthritis-Patienten in der Kohorte dermatologisch betreuter Psoriasis Patienten
|
n.a.
|
|
Psoriasis
|
VB-201-006-A
|
A randomized, double-blind, 12-week, dose ranging, placebo-controlled study to evaluate (1) the efficacy and safety of oral VB-201 on Carotid Artery and ascending Aorta PET 18FDG Uptake in psoriasis patients with abnormal baseline pet18fdg scans
|
II
|
|
Psoriasis
|
Gepard Long Life EXTENSION
|
Dokumentation und Auswertung gesundheitsbezogener Daten, die im Rahmen des epidemiologischen Studienprojectes "Gepard-Long Identifikation von Psoriasisarthritis-Patienten in einer Kohorte von Patienten mit Psoriasis erhoben werden."
|
n.a.
|
|
Psoriasis
|
DSC/03/2357/07
|
A randomized, double-blind, placebo-controlled,, multinational, multicentre, dose-finding parallel goup study to investigate safety and efficacy of ITF2357 in patients with moderate to severe plaque psoriasis
|
IIa
|
|
Psoriasis
|
C0168T45
|
A multicenter international observational study of long-term safety of infliximab (Remicade)
|
IV
|
|
Psoriasis
|
CAIN457ADE04
|
A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300mg s.c.) in comparison to continued standard treatment (4-weekly 300mg s.c.) in patients with moderate-severe plaque type psoriasis who achieved less than clear or almost clear skin (PASI response ≥75 to PASI <90) after 16 weeks under the standard dose of secukinumab
|
III b
|
|
Psoriasis
|
M13-674
|
A phase3, Multicenter, double-blind, randomized, parallel-arm, placebo-controlled study to evaluate the safety and efficacy of Adalimumab for treatment of nail psoriasis in subjects with chronic plaque psoriasis
|
III
|
|
Psoriasis
|
CAIN457A2317
|
A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severety Index at 6 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and ef
|
IIIb
|
|
Psoriasis
|
CAIN457ADE02
|
A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovaskular risk in patients with active chronic plaque-type psoriasis treated for up to 52 weeks with subcutaneous (s.c.) sekukinumab (300mg or 150mg).
|
IIIb
|
|
Psoriasis
|
MT-1303-E06
|
A Phase IIa, Multicentre, Randomised, Double Blind, Parallel Group, Placebo-Controlled Study to Evaluate Safety, Tolerability and Clinical Effiacy of MT-1303 in Subjects with Moderate to Severe Chronic Plaque Psorias
|
IIa
|
|
Psoriasis
|
ABP501
|
A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis
|
III
|
|
Psoriasis
|
CAIN457A2304
|
CAIN457A2304_Sculpture: A randomized, double-blind, multicenter study of subcoutaneous secukinumanb, assessing Psoriasis Area and Severity INDEX (PASI) response and maintenance of plague-type psoriasis on either a fixed dose regimen or on a retreatment at start od relapse regimen
|
III
|
|
Psoriasis
|
CAIN457A2307
|
CAIN457A2307_STATURE: A randomized, double-blind, double dummy , multicenter study to assess the safety, tolerability and long-term efficacy of intra-venous (10 mg/kg) and subcutaneous (300mg) secukinumab in subjects with moderate to severe chronic plague-type psoriasis who are partial responders to secukinumab
|
III
|
|
Psoriasis
|
A3921061
|
A phase 3, multi-site,open-label study of the long term safety and tolerability of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis
|
III
|
|
Psoriasis
|
A3921080
|
A phase 3, Multi-site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 and 1 Subcutaneous Dose of Entanercept in Subjects with Moderate to Severe Chronic Plague Psoriasis
|
III
|
|
Psoriasis
|
CAIN457A2211E1
|
A multicenter extension trial of subcutaneously adminstered AIN457 in patients with moderate to severe chronic plaque-type psoriasis
|
II
|
|
Psoriasis
|
P05495-806
|
A Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects with Moderate-to-Severe Chronic Plaque Posriasis
|
II
|
|
Psoriasis
|
LEO 80190-O21
|
Calcipotriol plus hydrocortisone in psoriasis vulgaris on the face and on the intertriginous areas;
|
III
|
|
Psoriasis
|
n.a.
|
A randomised placebo-controlled double-blind dose escalation study to evaluate the efficacy, safety and pharmacokinetic properties of the humanised CD4 monoclonal antibody BT061 in patients with chronic plaque psoriasis
|
I/Iia
|
|
Psoriasis
|
CAIN457A2211
|
A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN 457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moderate to severe chronic plaque-type psoriasis.
|
II
|
|
Psoriasis
|
1311.2
|
A 48 weeks study of three different dose regimes of BI 655066 administered subcutanoeusly in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comperator-controlled (ustekinumab), double blindwithin dose groups of BI 655066
|
II
|
|
Psoriasis Kind
|
CNTO1275PSO3006
|
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis
|
III
|
|
Psoriasis Kind
|
B1801035
|
A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept in the treatment of paediatric psoriasis patients in a naturalistic setting: a post-authorisation safety study
|
n.a.
|
|
Psoriasis Kind
|
027-008
|
A 2:1 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Fumaderm in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris (KIFUderm study)
|
IIIb
|
|
Psoriasis Kind
|
M04-717
|
M04-717: A Multicentre, Randomises, Double-Dummy-Blind Study Evaluiating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plague Psoriasis (Ps) Icorporating Administrative Changes 1 and 2 and Amendments 1 and 2
|
III
|
|
Psoriasis Arthritis
|
CNTO1275PSA3001
|
PSUMMIT I- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-LL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis
|
III
|
|
Psoriasis inversa
|
LP0133-1182
|
A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in treatment of mild to moderate inverse psoriasis
|
II a
|
|
Pruritus/atopische Dermatitis
|
M546102-EU 03
|
M546102-EU 03; A randomized, placebo-controlled-double-blind, parallel-group, multi-center Phase II b dose-finding study of M516102 in the treatment of pruritus associated with atopic dermatitis;
|
IIb
|
|
Atopische Dermatitis
|
R846-AD-1105
|
Random., doppelblinde ,placebokontrollierte Studie mit sequentiell ansteigender Dosierung zu klinischen Aktivitätsprüfung , Sicherheit, Verträglichkeit und Pharmakokinetik. Einer einzelnen i.v.Dosis von REG N846 bei refraktären moderaten bis schwerwiegenden Pruritus bei erwachsenen Patienten mit moderater bis schwerer Atopischen Dermatitis
|
Ib
|
|
Atopische Dermatitis
|
101-PG-PSC-150
|
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of an Add-on-Therapy of Depigoid House dust mites (HDM) in patients suffering from moderate to severe atopic eczema
|
III
|
|
Atopische Dermatitis
|
266-03/06
|
A multicenter, randomized, double-blind placebo-controlled, intra-individual-comparison phase Iia trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the topical treatment of mild to moderate atopic dermatitis
|
IIa
|
|
atopische Dermatitis
|
R668-AD-1334
|
A Phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherpy administered to adult patients with moderate-to-severe atopic dermatitis
|
III
|
|
Atopische Dermatitis
|
R668-AD-1415
|
A Phase 3, randomized, double-blind, placebo-controlled study Investigating the efficacy and safety of multiple dupilumab dose regimens administered as monotherapy for maintaining treatment response in patients with atopic dermatitis
|
III
|
|
Atopische Dermatitis
|
ZPL389/101
|
A randomized, double-blind, placebo controlled, parallel group study to determine the effects of 8 weeks treatment with oral ZPL-3893787 (30mg od X 56 days) on pruritus in adult subjects with moderate to severe atopic dermatitis
|
II
|
|
Atopische Dermatitis
|
GS29250
|
A phase II, randomized,double-blind,placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical corticosteroids
|
II
|
|
Atopische Dermatitis
|
CIM003JG
|
A Phase II, Randomized,double-blind,placebo-controlled,multiple-dose study to evaluate the safety, tolerability, and efficacy of CIM331 in Atopic Dermatitis patients who are inadequately controlled by or intolerant to topical therapy
|
II
|
|
Atopische Dermatitis
|
R668-AD-1424
|
A PHASE 3 STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF DUPILUMAB ADMINISTERED TO ADULT PATIENTS WITH SEVERE ATOPIC DERMATITIS WHO ARE NOT ADEQUATELY CONTROLLED WITH OR ARE INTOLERANT TO ORAL CYCLOSPORINE A, OR WHEN THIS TREATMENT IS NOT MEDICALLY ADVISABLE
|
III
|
|
Chronischer Pruritus
|
UKM10_0037
|
Aprepitant in histamine -refractory chronic pruritus: a multicenter, randomized, double-blnd, placebo-controlled, cross-over, phase II trial
|
II
|
|
pruritische Dermatosen
|
A-05610-2940
|
Wirksamkeit und Verträglichkeit von Azelastin.HC1 (4.4mg, od), Cetirizin (10mg, od) und Placebo bei Patienten mit allergischen und urtikariellen pruritischen Dermatosen
|
III
|
|
Prurigo
|
TCP 102
|
A randomized, double-blind, placebo-controlled, study of the Neurokinin-1 receptor antogonist VDP-737 in subjects with prurigo nodularis
|
II
|
|
Handekzem
|
LP0133-1180
|
A Phase 2a, Proof of Concept Trail, testing twice daily applications of LEO 124249 ointment 30mg/g in the treatment of chronic hand eczena
|
IIa
|
|
Mamillenekzem
|
n.a.
|
Bepanthen bei stillenden Müttern mit Mamillenekzem; Prüfung der Wirksamkeit, Verträglichkeit und Handhabung von Bepanthen Salbe zur Behandlung der Mamillitis bei stillenden Müttern;
|
AWB
|
|
Rhinokonjunktivitis
|
AL0704rP
|
A multicentre, multinational, randomised placebo-controlled double-blind pivotal clinical trial for evaluation of safety and efficacy of specific immunotherapy with a cocktail of recombinant major allergenes of Timothy Grass Pollen (Phleum pratense) adsorbed onto alluminium - hydroxide in patients with IgE-mediated allergic rhinoconjunctivits with/without controlles asthma (AMETHYST)
|
III
|
|
Rhinokonjunktivitis
|
AB0602
|
A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II/III follow-up study to assesslong-term efficacy and safety of three different does regimes of oralgen Grass pollen in patients with grass pollen-related allergic rhinoconjunktivitis
|
II/III
|
|
Allergische Rhinitis/ Rhinoconjuctivitis
|
AL0906rP
|
Open label phase ll multicenter clinical trial to evaluate safety during shortened uptitration of an allergoid gradd pollen preparation in adult patients with IgE mediated allergic rhinithis/ rhinoconjunctivitis with or without controlled broncial asthma
|
II
|
|
Birkenpollen Allergie
|
Basalit
|
Multizentrische, randomisierte, Plazebo-kontrollierte, 2-armige Doppelblindstudie zum Nachweis der Wrksamkeit und Verträglichkeit einer spezifischen Immuntherapie mit einer Aluminiumhydroxid-absorbierten hypoallergenen rekombinanten variante der Hauptallergens der Birkenpollen, rBET v1-FV, auf die Birkenpollen assozierte Soja-Allergie BASALIT (Birch Associated Soy Allergy and Immuno-Therapy)
|
IIb
|
|
Allergische Rhinitis/ Rhinoconjuctivitis
|
603-PG-PSC-191
|
Depigoid Birch Multicenter, placebo-controlled,long-term study of Depigoid Birch 5000vin adults an adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma
|
III
|
|
Rhinokonjunktivitis
|
6043-PG-PSC-192
|
A randomized, double-blind, parallel group, multicentre study to assess the efficacy and safety of four concentrations of Depigoid Phleum in patients with allergic rhinitis and/or Rhinoconjunctivitis with or without intermittent asthma
|
II
|
|
Rhinitis Rhinoconjunctivitis
|
603-PG-PSC-74
|
A randomised, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid birch pollen
|
III
|
|
Rhinitis Rhinoconjunctivitis
|
Depigoid Phleum Pro 2013
|
Non-interventional Study in Allergic Patients suffering from Grass Pollen induced rhinitis/Rhinoconjunctivits with or without Asthma. Retrospective assessment of the Efficacy of a perennial specific immunotherapy on the allergy symptomps/ Disease activity during the Pollen Season
|
n.a.
|
|
Rhinokonjunktivitis
|
V034.04
|
Randomised, double-blind, placebo-controlled, multinational, multi-cenre, Phase IIb/III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grasspollen rhinoconjunctivits
|
IIb/III
|
|
Urtikaria Neurodermitis
|
Bearbeitungsnummer - Ethik:837.340.0715875
|
Einfluss des Nahrungsergänzungsmittels Blagovitol auf die Lebensqualität von Patienten mit Chronischer Urtikaria und Neurodermitis
|
n.a.
|
|
Chronische Urtikaria
|
n.a.
|
Chronic Urticaria-Long Term Assessment of Effects of Rupatadine. A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine.
|
III
|
|
Chronische Urtikaria
|
RPCE98A1901
|
Open, Phase III Multicentre Trial, assessing the safety and efficacy of 15mg Efletrizine Capsules administered orally twice a day, for up to one year, to adult patients with chronic urticaria
|
III
|
|
Chronische Urtikaria
|
n.a.
|
Behandl. der chron.Urtikaria mit Histaglobin
|
n.a.
|
|
Chronische Urtikaria
|
n.a.
|
Behandlung der chronischen Urtikaria mit autologem Vollblut- Eigenblutbehandlung der Urtikaria
|
n.a.
|
|
Chronische Urtikaria
|
IGE025E5003
|
ASSURE-CSU: Assessment of the Economic and Humanistic Burden of Chronic Spontaneous/idiopathic Urticaria Patients
|
n.a.
|
|
Chronische Urtikaria
|
DC1-CT-001/01
|
A phase II, multicentre, randomised, double-blind, placebo controlled, parallel group study to investigate the efficacy of 100, 200 and 300 mg t.i.d. Fluormethylhistidine (FMH) in patients with chronic urtikaria;
|
II
|
|
Chronische Urtikaria
|
Histaminintoleranz
|
prospektive Beobachtungsstudie: histaminintoleranz bei chronisch spontaner Urtikaria
|
|
|
Chronische Urtikaria
|
001/2002
|
Symbioflor bei chron. Urtikaria, Symbiopharm; Behandlung der chronischen Urtikaria mit Mikrobiologika
|
n.a.
|
|
Chronische Urtikaria
|
GX29107
|
Eine Multizentische, Randomisierte, Doppelblinde, Placebo-Kontrollierte Pilotstudie mit Quilizumab bei Patienten mit refraktärer chronisch-spontaner Urtikaria
|
II
|
|
Urtikaria
|
|
A two center double blind placebo controlled study in parallel desing to asses the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihisatmineresitant cold contact urticaria (CCU)
|
II
|
|
Chronische Urtikaria
|
CIGE025E2201
|
CIGE: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-II-Studie zur Bestimmung der Wirkungsweise von Omalizumab bei Patienten mit chronischer idiopathischer Urtikaria (CIU), die unter Behandlung mit Antihistaminika (H1) symptomatisch bleiben
|
II
|
|
Urtikaria
|
CIGE025EDE16
|
X-ACT: A randomized, double-blind, placebo-controlled, multicenter, 28-week treatment study with an 8 week follow-up period to investigate the impact of subcutaneous Omalizumab on quality of life measures as well as the
|
IIIb
|
|
Chronische Urtikaria
|
Q4883g
|
Glacial: A Phase III, Multicentre, Randomized, Double-Blind, Placebo Controlled Safety Study of Xoliar (Omalizumab) in Patients with Chronix Idiopathic Urticaria (CIU) who remain symptomatic despite Treatment with H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
|
III
|
|
Chronische Urtikaria
|
Q4882g
|
A Phase III, Multicenter, Randomized, Double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy, response duration and safety of Xolaire (Omalizumab) in patients with chronic idiopathic urticarial (CIU) who remain symptomatic despite antihistamine treatment (H1) (ASTERIA II)
|
III
|
|
Chronische Urtikaria
|
CIGE025ADE05
|
X-Cuisite # CIGE025ADE05-Novartis; A randomised, 24 week, double-blind, placebo-controlled, parallel-group, multicentre study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE against thyreoperoxidase;
|
II
|
|
Chronische Urtikaria
|
A00394/ RPCEA0501
|
A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacyand safety of Levocetirizine 5 mg oral capsules once daily in the morning vs. Desloratadine 5 mg oral capsules once daily in the morning in patients suffering from chronic Idiopathic Urticaria(CIU)
|
IV
|
|
Chronische Urtikaria
|
MIARCU 01/2008
|
Wirksamkeit und Verträglichkeit von Miltefosin bei der Behandlung der Antihistaminika-resistenten chronischen Urtikaria;
|
II
|
|
Chronische Urtikaria
|
Q4577g
|
A Phase II, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of Xolair in patients with chronic idiopathic urticaria (CIU) who remain symptomatic with antihistamine treatment H1);
|
II
|
|
Urtikaria
|
AECUDATT
|
Multicenter, double-blind, dose escalating study to compare the effects of 5 mg, 10 mg and 20 mg of Desloratadine in patients with acquiered co-ed urtikaria (ACU)
|
II
|
|
Chronische Urtikaria
|
P04849
|
A study of the efficacy, safety and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets ( 5mg, 10 mg or 20 mg once daily)
|
IV
|
|
Angioödem
|
HCR: 565/DY
|
Open label single ascending intravenous dose study to assess the tolerability and efficacy of DX-88 administered following onset of peripheral and /or facialedema of abdominal symptoms in patients with angioedema
|
n.a.
|
|
HAE
|
CSL930_3002
|
An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema
|
IIIb
|
|
HAE
|
HGT-FIR-086
|
A Multicenter, open-label, non-randomized study to assess the pharmacokinetics, tolerability, and safety of a single subcutaneous administration of icatibant in children and asolescents with hereditary angioedema
|
III
|
|
HAE
|
0624-206
|
A Phase 2, Randomized, Double Blind, Multicenter, Dose Ranging Crossover Study to Evaluate the Safety and Effiacy of Subcutaneous Administration of CINRYZE (C1 Esterase Inhibitor(Human)) with Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
|
II
|
|
HAE
|
BCX4161-203
|
A Phase 2A Double-Blind, Placebo-Controlled 2-Period Crossover Study to evaluate the safety and efficacy of BCX4161 As a prophylactic treatment to reduce the frequency of attacks in subjects with hereditary angioedema
|
IIa
|
|
HAE
|
CSL830_2001
|
Eine offene Cross-over Dosisfindungssudie zur Evaluierung von Pharmakokinetik. Pharmakodynamik und Sicherheit der subkutanen Verabreichung eines aus menschlichem Plasma gewonnenen C1-Esterase-Inhibitors bei Patienten mit hereditärem Angioödem
|
n.a.
|
|
HAE
|
JE049-3101
|
Open-label, Multicenter Study to Evaluate Safety, Local Tolerability., Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema - EASSI
|
IIIb
|
|
HAE
|
JE 049#2102
|
Randomized, Double Blind, Controlled, Parallel-Group, Multicenter Study of a Subcutaneous Formulation of Icatibant vs Oral Tranexamic Acid for the Treamentof Hereditary Angioedema (HAE)
|
n.a.
|
|
Mastozytose
|
PA101-SM-02
|
Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis
|
Iia
|
|
Mastozytose
|
AB06006
|
Eine 24-wöchige, verlängerbare, prospektive, multizentrische, randomisierte, doppelblinde, plazebokontrollierte Phase III Studie mit zwei 1:1 randomisierten Parallelgruppen zum Vergleich der Wirksamkeit und Sicherheit von Masitinib bei 6mg/kg/Tag mit Plazebo bei der Behandlung von Patienten mit schwelender systemischer, indolenter systemischer oder kutaner Mastozytose, die zu Beeinträchtigungen führt.
|
III
|
|
Mastozytose
|
MICUMA
|
Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis
|
II
|
|
Influenza Vaccine
|
810601
|
An open label Phase III study of a vero cell-derived whole virus H5N1 influenza vaccine to assess the immunogenicity and safety and to investigate the need for and timing of a booster vaccination;
|
III
|
|
Influenza Vaccine
|
n.a.
|
Single-blind randomized controlled Phase II/III study to investigate the immunogenicity and safety after a single vaccination with one of three different lots of an inactivated influenza vaccine (whole virion, vero-cell derived) in comparison to a licensed egg derived influenza vaccine for season 2004/2005
|
II/III
|
|
Hautinfektionen
|
DAP002
|
Daptomycin # DAP002, Site 09; A multicentre, randomised, assessor-blind study to evaluate eficcaca and safety of Daptomycin versus Vancomycin or Teicoplanin for treatment of complicated skin and soft tissue infection (cSSTI)
|
III
|
|
Hautinfektionen
|
BAY12-8039 / 11974
|
A prospective, randomized, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400mg QD to intravenous piperacillin/tazobactam 4.0/5.0g IV every 8 hours followed by oral amoxicillin/clavularic acid tablets 875/125mg very 12 hours for the treatment of patients with complicated skin and skin structure infections
|
IIIb
|
|
Hautinfektionen
|
TMC-ORI-10-02
|
A multicenter, double-blinded, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin für the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection (SOLOII)
|
III
|
|
Hautinfektionen
|
P903-07
|
A phase 3, Multicenter, Randomized,Double-blind,Comparative Study to Evaluate the Safety and Efficacy of Ceftalroline Versus Vancomycin plus Aztreonam in Adult Subjects with complicated skin and skin structure infection
|
III
|
|
Hautinfektionen
|
RO4908463/ WI18274
|
A phase II prospective, open label, randomized, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with complicated skin structure infections requiring hospitalization
|
II
|
|
Acne Vulgaris
|
TT-AVUGANE-Acne-02
|
A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically apllied Avugane of different concentrations in subjects with mild to moderate acne vulgaris
|
IIb
|
|
Acne Vulgaris
|
DS207E-03
|
Randomisierte, doppelblinde, placebokontrolollierte Phase II-Studie zur Bestimmung der Wirksamkeit und der Sicherheit von DGLA-Creme zur topischen Anwendung bei Patienten mit leichter bis mittleschwerer Acne vulgaris
|
II
|
|
Hidradenitis Suppurativa
|
M11-313
|
A phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
|
III
|
|
Hidradenitis Suppurativa
|
M12-555
|
A phase 3 open-label study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
|
III
|
|
Rosacea
|
RD.03.SPR.40173
|
Efficacy and safety of CD5024 1 % cream versus metronidazole 0,75 % cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36 week extension period
|
III
|
|
Rosazea
|
FX2015-10
|
A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of two Different Doses of a Topical Minocycline Foam Compared to Vehicle in the Treatment of Papulopustular Rosacea
|
II
|
|
Impetigo, Kind
|
P-110881-01
|
A phase lll 2 arms, multicenter, randomised, double-blind study to asses the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients with impetigo
|
III
|
|
entzündliche Hauterkrankungen
|
n.a.
|
Identifizierung und Validierung von neuen Zielmolekülen für die Therapie von entzündlichen Hauterkrankungen
|
n.a.
|
|
Bilateral Primary Axillary Hyperhidrosis
|
191622-506
|
A Multicenter, Open Label Study of the Safety of BOTOX (Botulinum Toxin, Type A) Purified Neurotoxin Complex for the Treatment of Bilateral Primary Axillary Hyperhidrosis
|
III
|
|
Autoimmun Erkrankungen
|
CERL080ADE08
|
Measurement and Analysis of Patient reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolate (MPA)
|
III
|
|
Bullöses Pemphigoid
|
The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Study
|
Blister - IIT: The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Study, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid
|
IV
|
|
Pemphigus vulgaris
|
WX17796
|
CELLCEPT (Mycophenolate Mofetil) in Pemphigus vulgaris
|
III
|
|
Bullöse Autoimmundermatosen
|
Popgen
|
Untersuchung der genetischen Suszeptibilität zur Ausbildung bullöser Autoimmundermatosen
|
IV
|
|
Systemische Sklerodermie
|
AC-055C303
|
Long-term, single-arm, open-label extension study of protocols AC-055C301 and AC -055C302 to assess the safety, tolerability and efficacy of macitentan in subjects with ischemic digital ulcers associated with systemic sclerosis
|
III
|
|
Pemphigus vulgaris
|
DRKS 00000566
|
IA PEM: Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem-study)
|
|
|
Onychomykose
|
CSFO327N2302
|
A randomized, double-blind,vehicle-controlled,multicenter, parallel-group study to assess the efficacy, safety and tolerability of topical terbinafine hydrogen chloride (HCI)formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenails onychomycosis
|
III
|
|
Onychomykose
|
CSFO327N2303
|
A randomized, open-label, active-controlled, multicenter, parallel group study to assess the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride (HCI) formulation versus 5 % amorolfine nail lacqueur for 48 weeks of treatment in patients with mild to moderate toenail onchomykosis;
|
III
|
|
Onychomykose
|
RD.03.SPR40026
|
A multicentre, randomized, parallel groups, vehicle and active controlled study of Amorolfine 4 % and 10 % nail lacqueur new formulation in the topical treatment of distal and lateral subungual toenail onchomycosis;
|
II
|
|
Onychomykose
|
CSFO327L2302
|
A multicenter, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of new oral formulation terbinafine in patients witch onychomycosis of the toenails
|
III
|
|
Aktinische Keratose
|
X-03016-3271
|
Long-term effects of Aldara 5% cream and Solaraze 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA)
|
IV
|
|
Aktinische Keratose
|
X-03016-3284
|
Long-term effects of Aldara 5% cream and Solaraze 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carcinoma (LEIDA 2)
|
IV
|
|
Chronisch venöse Insuffizienz
|
n.a.
|
A 12-week, double blind, randomised, placebo-controlled, multicentre trial to evalute efficacy and tolerability of Antistax film-coated tablets, 720 mg/day orally, in male and female patients suffering from chronic venous insufficiency
|
III
|
|
Chronisch venöse Insuffizienz
|
EDX09/01
|
Multicentre, double-blind, placebo-controlled,randomised clinical study to assess the efficacy and safety of Doxium 500 three times daily in patients suffering from chronic venous inusfficiency (CVI) CEAP Class C3 or C4
|
IV
|
|
Chronisch venöse Insuffizienz
|
1138.10 (HCR:984/BIG)
|
A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of AntistaseR film-coated tablets 360 mg/day orally, in male and female patients suffering from chronic venous insuffiancy
|
III
|
|
chronisch venöse Insuffizienz
|
DX 2000/01 SSS
|
Multicentre, double-blind, placebo controlled, randomised clinical study to assess the efficacy and safety of Doxium 500 three times daily in patients suffering from chronic venous insufficiency (CVI) CEAP Class 3,4 or 5
|
IV
|
|
chronisch venöse Insuffizienz
|
CL3-05682-097-DEU
|
Efficacy of Daflon 500mg (2 tablets daily – 1000mg of micronized purified flavonoid fraction) in the treatment of patients suffering from vesperal edema related to chronic venous insufficency. International, multicenter, double-blind, randomized, placebo-controlled study
|
III
|
|
chronisch venöse Insuffizienz
|
1138.4 (HCR:827/BIG)
|
Eine 12-wöchige, doppelblinde, randomisierte, plazebokontrollierte, multizentrische Studie zur Untersuchung der Wirksamkeit und Verträglichkeit von Antistax Filmtabletten, 360mg/Tag oral, an männlichen und weiblichen Patienten mit chronisch venöser Insuffizienz
|
III
|
|
chronisch venöse Insuffizienz
|
9401-00C
|
Feasibility Clinical Protocol for the Percutaneous Venous Valve Bioprosthesis (PVVB)
|
n.a.
|
|
chronisch venöse Insuffizienz
|
9301-99C
|
Feasibility Clinical Protocol for the Monocusp Venous Valve Bioprosthesis (MVVB)
|
n.a.
|
|
chronisch venöse Insuffizienz
|
GSOB 301
|
An open label randomised stratifies, between subject, multicenter study to compare the safety and efficacy of Apligraf and a Duoderm R dressings in the treatment of chronic venous insufficiency leg ulcers
|
III
|
|
Ulcus Cruris vensosum
|
Collagenase OI DEB IMCR-D 2 P 3
|
Double-blind, placebo-controlled, comparative trial to evaluate the wound cleansing effect of Novuxol in patients with venous ulcus cruris
|
III
|
|
Wundheilung
|
BSH-12
|
Offene, verblindet ausgewertete, prospective, kontrollierte, randomisierte multizentirsche klinische Studie Phase lll zum intraindividuellen Vergleich der Wirksamkeit und Verträglichkeit von Oleogel-S10 im Vergleich zur Standardtherapie hinsichtlich der Beschleunigung der Wundheilung an Spalthautentnahmestellen mit Oleogel-S10.
|
III
|
|
Malignes Melanom
|
AJCC 2002
|
Phase III Protokoll zur Therapieoptimierung der adjuvanten Behandlung des malignen Melanoms im Stadium III (AJCC 2002): Intermittierende hochdosierte i.v.-Gabe von Interferon- alpha – 2b vs. Standard hochdosierte Interferon – alpha – 2b – Therapie.
|
III
|
|
Malignes Melanom
|
n.a.
|
Adjuvante Therapie im Stadium II beim malignen Melanom mit Interferon-alpha 2a: Intermittierende, intermediäre s.c.-Gabe versus Kontinuierliche intermediäre s.c.-Gabe
|
n.a.
|
|
Malignes Melanom
|
CA186006
|
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage iV Melanoma;
|
II
|
|
node-positive melanoma
|
198-135
|
A randomized Phase II / III Trial of SCH 54031 PEG12000 Inerferon alfa-2b (PEG Intron) vs. INTRON A as Adjuvant Therapy for Melanoma
|
II /III
|
|
HSV Typ 1 Infektion
|
101-001
|
A randomized, placebo-controlles, active comparator, observer-blinded multicentre phase II trial to evaluate the efficacy and safety of D2D001 in the treatment of HSV type 1 infection in the region of the mouth and the opneings of the nose
|
II
|
|
Genitalherpes
|
HS2B3010
|
A randomised double-blind study to compare Valaciclor 500 mg twice daily given for three days with the standard five days course as episodic treatment for recurrent genital herpes
|
n.a.
|
|
Genitalwarzen
|
1426-IMIQ
|
An Open-Label, Multicenter, Safety and Efficacy Trial of Topical Imiquimod 5% Cream in the Treatment of External Anogenital Warts to Demonstrate Sustained Clearnace of Warts in Comparison with Ablative Methods
|
IIIb
|
|
erektile Dysfunktion
|
SDN-D-98-002
|
Studie zur Beurteilung der Zufriedenheit mit dem Behandlungsergebnis nach Therapie mit Viagra
|
n.a.
|
|
Borreliose
|
A2301 PXL202666
|
Borreliose: A Phase 3 randomized, double-blind, placebo-controlled study of SHB004 (10% topical azithromycin) administered locally twice daily for three consecutive days for the prevention of Borreliosos in subjects bitten by a tick
|
III
|
|
normale und empfindliche Haut
|
LaMer2013
|
Verträglichkeit und Anwendbarkeit von Inhaltsstoffen der Lamer Cosmetics AG Produkten insbesondere Einfluss von Meeresschlick, Meeresschlickextrakten und Meersalz auf die normale und empfindliche Haut. Monozentrische, verblindete, randomisierte Studie
|
n.a.
|
|
gesund
|
837.508.14
|
In-use test of sebamed Anti-Ageing Q10 Protection Cream and Firming Body Lotion for facial and body care
|
|
|
gesund
|
Flavo2010
|
Untersuchung der Beeinflussung der Phamakokinetik (Absorption und Bioverfügbarkeit) durch Flavonoide Quercetin und Naringin auf einen Cytochrom P450 3A4 präsiystemisch metabolisiertem Wirkstoff (Midazolam) und auf den präsystemischen Effluxtransport eines P-Glykoprotein-Substrats (Talinilol) in gesunden Probanden in einer kontrollierten, offenen, 3-fachen Cross-Over-Studie und einer kontrollierten, offenen, 4-fachen Cross-Over-Studie.
|
I
|
|
gesund
|
n.a.
|
Untersuchung des Einflusses einer verzögerten Freigabe aufdie Absorption und Bioverfügbarkeit intestinal metabolisierter Arzneistoffe anhand von einer Einmaldosis von Simvastatin 20 mg als Modellsubstanz bei gesunden Probanden ein einer offenen randomisierten 3-fach Cross-Over-Studie
|
I
|
|
gesund
|
1101_V19-PT2_01_Pilot_III
|
Safety and Efficacy Study of the V19 Laser Hair Removal Device in Adult Female Subjects
|
n.a.
|
|
gesund
|
Aciclovir 2011
|
Untersuchung der Beeinflussung der Pharmakokinetik (Absorption und Bioverfügbarkeit) eines parazellulär aufgenommenen Wirkstoffs (Aciclovir) durch Chitosan in gesunden, freiwilligen Probanden in einer kontrollierten, offenen, dreifachen Cross-Over-Studie
|
I
|
|
Hair Removal
|
1205_ Competitive Benchmarking Study
|
Evaluation and Comparison of Efficacy of Four Hair Removal Devices (V19 Laser, Venus Naked Skin IPL, Philips Lumea IPL and Remington iLight Pro IPL) in Adult Female Subjects
|
AWB
|
|
Hair Removal
|
CRIES - 2010
|
Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla Creme, Polidocanol)
|
n.a.
|
|
Narben
|
MRZ90011_0028_3
|
A prospective, intra-individual randomized, observed blind, controlled Investigation to investigate the effectiveness and safety of overnight intensive patch (OIP) over 12 to 24 weeks in post dermatological surgery scars
|
n.a.
|
|
Ästhetik
|
Y-52-52120-214
|
A phase III, randomised, double.blind, placebo-controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of BTX-A-HAC NG following repeated treatments in this indication
|
III
|
|
Rejuvenation
|
0613_SC50000-01
|
Assessing Discomfort of Fractional Laser Skin Rejuvination Devices - Prototypes vs. Philips
|
AWB
|
|
n.a.
|
068-010
|
APQ_Adherence Studien-Nr.: 068-010
|
n.a.
|
|
n.a.
|
1108 V19-PT03 01
|
Safety and Efficacy Study of the V19 Laser Hair Removal Device in Adult Female Subjects
|
n.a.
|
International Medical Services